Drug Trial News

RSS

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer - as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status - according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM).

10 Dec 2024

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

The antiviral drug tecovirimat did not reduce the time to lesion resolution or have an effect on pain among adults with mild to moderate clade II mpox and a low risk of developing severe disease, according to an interim data analysis from the international clinical trial called the Study of Tecovirimat for Mpox (STOMP).

10 Dec 2024

New triplet therapies show promise for relapsed and newly diagnosed leukemias

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or refractory and newly diagnosed leukemias.

9 Dec 2024

First-in-class monoclonal antibody shows promise for rare, aggressive hyperinflammatory condition

Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.

9 Dec 2024

Novel drug combination shows promise for CLL treatment

A novel, fixed-duration drug combination - consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug - shows deep and durable responses in patients with chronic lymphocytic leukemia (CLL), Dana-Farber Cancer Institute investigator Jennifer Brown, MD, PhD, reports at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition, on behalf of the trial investigators.

9 Dec 2024

Antibody trials show encouraging results in patients with high-risk forms of two blood cancers

Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.

9 Dec 2024

Breakthrough treatment improves survival rates for children with B-ALL

Just days before his fourth birthday, Santiago was diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), the most common cancer in children.

9 Dec 2024

Filgotinib offers new promise for managing Crohn’s disease

Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's disease, achieving clinical and endoscopic remission in phase 3 trials. The findings highlight its potential as a novel therapeutic option for difficult-to-treat patients.

8 Dec 2024

Phase one trial explores novel immunotherapy for breast cancer

A groundbreaking phase one clinical trial exploring a novel cell-based immunotherapy for breast cancer has been accepted for publication in JAMA Oncology.

5 Dec 2024

L-arginine shows potential in treating spinocerebellar ataxia type 6

A team led by Specially Appointed Associate Professor Tomohiko Ishihara and Professor Osamu Onodera at Niigata University, along with Professor Yoshitaka Nagai at Kindai University, conducted a randomized, double-blind trial on the efficacy and safety of L-arginine in treating Spinocerebellar ataxia type 6 (SCA6).

3 Dec 2024

Concizumab shows promising results for hemophilia patients

For people with the bleeding disorder hemophilia, life can seem like one continuous state of alertness. If they accidentally cut their finger while chopping vegetables, they have to immediately administer the clotting factor protein that their body either lacks or does not produce enough of.

2 Dec 2024

New injection treatment could be a game-changer for people with asthma and COPD

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further treatment by 30%.

27 Nov 2024

First U.S. trial uses non-viral CRISPR to correct sickle cell mutation

UCSF Benioff Children's Hospital Oakland is enrolling patients in an innovative clinical trial that seeks to cure sickle cell disease.

26 Nov 2024

Tirzepatide cuts diabetes risk by 90% in obese patients, study shows

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the results of a new study led by investigators at Weill Cornell Medicine, NewYork-Presbyterian, Yale School of Medicine and other institutions.

26 Nov 2024

Temozolomide and radiation combination improves survival in low-grade glioma patients

Previous
1
...
6
7
8
9
10
11
12
...
1151
Next

Drug Trial News

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Daratumumab treatment shows promise for high-risk smoldering multiple myeloma in phase 3 trial

Interim analysis of STOMP study finds no efficacy for tecovirimat in mild to moderate Mpox cases

New triplet therapies show promise for relapsed and newly diagnosed leukemias

First-in-class monoclonal antibody shows promise for rare, aggressive hyperinflammatory condition

Novel drug combination shows promise for CLL treatment

Antibody trials show encouraging results in patients with high-risk forms of two blood cancers

Breakthrough treatment improves survival rates for children with B-ALL

Filgotinib offers new promise for managing Crohn’s disease

Phase one trial explores novel immunotherapy for breast cancer

L-arginine shows potential in treating spinocerebellar ataxia type 6

Concizumab shows promising results for hemophilia patients

New injection treatment could be a game-changer for people with asthma and COPD

First U.S. trial uses non-viral CRISPR to correct sickle cell mutation

Tirzepatide cuts diabetes risk by 90% in obese patients, study shows

Temozolomide and radiation combination improves survival in low-grade glioma patients

Cetuximab performs better than durvalumab in treating head and neck cancers

Titrzepatide reduces risk of death or worsening heart failure for patients with obesity-related heart failure

Oral medication sodium oxybate shows promise for treating laryngeal dystonia

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Latest News